高级检索
    刘金来, 李苏华. PCSK9抑制剂Evolocumab和Alirocumab降低血脂和减少心血管事件的有效性和安全性评价[J]. 循证医学, 2015, 15(6): 334-338. DOI: 10.3969/j.issn.1671-5144.2015.06.007
    引用本文: 刘金来, 李苏华. PCSK9抑制剂Evolocumab和Alirocumab降低血脂和减少心血管事件的有效性和安全性评价[J]. 循证医学, 2015, 15(6): 334-338. DOI: 10.3969/j.issn.1671-5144.2015.06.007
    shu
    LIU Jin-lai, LI Su-hua. Efficacy and Safety of Evolocumab and Alirocumab in Reducing Lipids and Cardiovascular Events[J]. Journal of Evidence-Based Medicine, 2015, 15(6): 334-338. DOI: 10.3969/j.issn.1671-5144.2015.06.007
    Citation: LIU Jin-lai, LI Su-hua. Efficacy and Safety of Evolocumab and Alirocumab in Reducing Lipids and Cardiovascular Events[J]. Journal of Evidence-Based Medicine, 2015, 15(6): 334-338. DOI: 10.3969/j.issn.1671-5144.2015.06.007
    shu

    PCSK9抑制剂Evolocumab和Alirocumab降低血脂和减少心血管事件的有效性和安全性评价

    Efficacy and Safety of Evolocumab and Alirocumab in Reducing Lipids and Cardiovascular Events

      摘要
      • HTML全文
      • 参考文献(12)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回